Table 1. SENP7-Interacting Proteins along with SUMOylation Site and Their Function in Disease.
| Protein Name | Condition of Identification | SUMOylation Site | SUMO Interaction Motif (SIM) | Function | Disease Reported |
|---|---|---|---|---|---|
| NCoR1a | DSS | 145/DAKK |
– | repress NF-κB and AP-1 genes (Tiefenbach et al., 2006; Perissi et al., 2004) | breast cancer |
| 1068/IKQE |
(Zhang et al., 2006) | ||||
| 1333IKFD | |||||
|
| |||||
| Notch1a | DSS | 1607/FKRD |
1575-1579/VLVVL | stem cell development, γδ T cell activation (Stier et al., 2002; Washburn et al., 1997) | IBD, cancer |
| 1712/VKSE |
(Dahan et al., 2011) | ||||
| 2242/AKPE | |||||
|
| |||||
| CBX5a | control/DSS | 84/EKSE | – | transcriptional activator | breast cancer (Bawa-Khalfe et al., 2012) |
|
| |||||
| PLK1a | control/DSS | 358/EKEE | – | cell cycle (Wen et al., 2017) | colorectal cancer (Takahashi et al., 2003) |
|
| |||||
| Vimentina | control/ DSS | 373/MKEE | – | epithelial-mesenchymal transition (Bawa-Khalfe et al., 2012) | IBD (Andoh et al., 2002) |
|
| |||||
| Birc2 | control/ DSS | 38/EKMK | 424-428/IVSVL | anti-apoptotic | IBD (Grabinger et al., 2017) |
|
| |||||
| 40/MKFD | 575-579/IVFIP | ||||
|
| |||||
| CARD9 | DSS | 165/LKEE | 22-26/ISVID | regulate gut microbiota | IBD (Lamas et al., 2016) |
|
| |||||
| 219/MAKE |
343-347/IEAIL | ||||
| 391/EKAD | |||||
|
| |||||
| S100A9 | DSS | 35/SKKE |
– | calcium-binding protein | IBD (Lee et al., 2012) |
| 51/MKKE | |||||
|
| |||||
| E3 ubiquitin ligase SIAH2 | control/DSS | – | 250-254/VLLIG | ubiquitination | prostate cancer (Qi et al., 2013) |
a
SUMOylation of these proteins is known.